Christine Thai, MD
Rheumatology · Huntington Beach, CANPI 1043224587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Amgen at 29.8% of the total. Reporting peaked in 2019 at $2,357 and has fallen 65.6% since, to $812 in 2025.
Across 437 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$1K
- Novartis$1K
- Johnson & Johnson$577
- UCB, Inc.$380
- Lilly USA, LLC$278
- plus $2K from 19 others
Across 692 payments — averaging $12,482 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5.7M
- AbbVie$2.4M
- Janssen Research & Development, LLC$324K
- E.r. Squibb & Sons, L.L.C.$141K
- Novartis$37K
What the payments were for
- Food & beverage$7,37199%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 166 | $2,228 |
| AbbVie | 72 | $1,451 |
| Novartis | 58 | $1,035 |
| Johnson & Johnson | 33 | $577 |
| UCB, Inc. | 14 | $380 |
| Lilly USA, LLC | 12 | $278 |
| GSK | 14 | $268 |
| Pfizer | 15 | $194 |
| Boehringer Ingelheim | 7 | $184 |
| E.r. Squibb & Sons, L.L.C. | 9 | $179 |
| Organon | 13 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $90 |
| Genentech USA, Inc. | 4 | $84 |
| Sanofi | 3 | $61 |
| AstraZeneca | 3 | $54 |
| Antares Pharma, Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $42 |
| Forte Bio-pharma LLC | 1 | $34 |
| Aurinia Pharma U.S., Inc. | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Merck | 2 | $27 |
| Exact Sciences | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$125
How this compares
$7,483 in reported general payments places this provider in the 65th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 39 | $244,015 |
| Humira(Cf) PenAdalimumab | 33 | $222,714 |
| Enbrel SureclickEtanercept | 24 | $174,805 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $84,782 |
| OrenciaAbatacept | 13 | $75,918 |
| Orencia ClickjectAbatacept | 11 | $72,671 |
| OrenciaAbatacept/Maltose | 12 | $51,216 |
| SavellaMilnacipran Hcl | 32 | $21,992 |
| Hydroxychloroquine Sulfate | 301 | $12,086 |
| Mycophenolate Mofetil | 20 | $10,051 |
| MethotrexateMethotrexate Sodium | 277 | $8,339 |
| Leflunomide | 125 | $6,518 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 149 | $4,266 |
| Celecoxib | 92 | $3,887 |
| Lidocaine | 15 | $3,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella, Synthroid | $1,451 | $269,226118 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $179 | $127,13425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 808 rheumatology providers in California.
Other rheumatology in Huntington Beach
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.